Live Biotherapeutics Drug Discovery Services for Colorectal Cancer (CRC)

Evidence has shown that taking probiotics is a protective approach for proper maintaining of healthy gut microbiota and also reducing the risk of colorectal cancer (CRC). Equipped with world-leading technology platforms and industry-leading expertise in the development of next-generation probiotics (NGPs), Creative Biolabs has accumulated substantial experience in the NGPs identification for single strains and blends to help our clients in the development of probiotics for the treatment of CRC. Our comprehensive portfolio of microbial and stability testing analysis fully supports all the processes of good manufacturing practice (GMP).

Introduction of CRC

CRC is the third most commonly diagnosed cancer with more than 1 million new cases annually and is responsible for the death of more than 500,000 people. CRC develops by the accumulation of mutations, starting in stem cells at the base of the crypts, and usually begins as a non-cancerous polyp. CRC incidence can be associated with several genetic factors such as germline mutations in the mismatch repair genes and adenomatous polyposis coli (APC) gene. In addition to genetic predispositions, environmental factors such as lifestyle and diet play an important role in CRC risk. This lifestyle and diet lead to disturbances in the intestinal environment, including the luminal content and microbiota. The microbiota plays a role in generating biochemical and physiological conditions that may increase the number of colonic pre-neoplastic lesions. Modulation of the unbalanced gut microbiota can reduce the risk of colon cancer risk.

Potential mechanisms of action of probiotics in the improvement of the physico-chemical conditions and the microbiota balance in the colon while producing beneficial metabolites and reducing toxic compounds. Fig.1 Potential mechanisms of action of probiotics in the improvement of the physico-chemical conditions and the microbiota balance in the colon while producing beneficial metabolites and reducing toxic compounds. (Kahouli, 2013)

CRC and Probiotics

Studies showed the effect of probiotics on manipulating the composition of gut microbiota, thus positively affect the host by improving intestinal barrier integrity, inhibiting the growth of pathogens, reducing the metabolism of pro-carcinogenic substances. Based on their anticancer properties, probiotics can be used in combination with conventional CRC therapies, such as surgery and chemotherapy. Data obtained suggest probiotics are effective in preventing and inhibiting the growth of intestinal cancer. The administration of probiotics along with CRC treatment may alleviate the secondary effects related to chemotherapy. Moreover, the prevention of cancer therapy-induced mucositis by probiotics has been investigated in randomized clinical trials with some promising results. Furthermore, clinical reports show that probiotics can improve the integrity of the gut mucosal barrier and decrease infectious complications in surgical CRC patients.

Table.1 Effect of probiotics intervention for prevention or/and treatment of CRC in some clinical trial studies. (Javanmard, 2018)

Type of intervention Patients Probiotic strain Outcome
Prevention 10 CRC and 20 healthy patients Lactobacillus gasseri (LG21) A deterioration of the intestinal environment was observed in colorectal cancer patients in comparison to the healthy controls, and the intestinal environment improved when probiotics were taken.
Prevention of post-operative complication 100 CRC patients undergoing surgery
(placebo group/probiotics group n=50/50)
Lactobacillus plantarum
Lactobacillus acidophilus
Bifidobacterium longum
Improvement in the integrity of the gut mucosal barrier and
decrease in infections complications.
Chemotherapy and radiation therapy related toxicity 156 CRC patients undergoing surgery
(placebo group/probiotics group n=81/75)
Enterococcus faecalis
Clostridium butyricum
Bacillus mesentericus
Probiotic treatment reduces superficial incisional surgical site infections (SSIs) in patients undergoing CRC surgery.
150 CRC patients undertreated Lactobacillus rhamnosus GG Patients had less diarrhea, less abdominal pain, less hospital care, and had fewer
chemo dose reductions due to bowel toxicity.

NGPs Discovery Service at Creative Biolabs

Our specialized techniques and strategies for the development of NGPs are specifically catered to facilitate our customers’ research and project development. Creative Biolabs offers NGPs as single strains or blends, all validated by gold-standard clinical trials. Each robust strain or strain-combination provides an array of benefits sure to meet every specific need of our global clients. Our seasoned scientists are experts in NGPs project evaluation through technical, economic, sustainability, and engineering to translate from lab scale to scale up.

Please feel free to contact us for a quote and further discussion with our scientists.

References

  1. Kahouli, I.; et al. Probiotics in colorectal cancer (CRC) with emphasis on mechanisms of action and current perspectives.Journal of medical microbiology. 2013, 62(8): 1107-23.
  2. Javanmard, A.; et al. Probiotics and their role in gastrointestinal cancers prevention and treatment; an overview. Gastroenterology and hepatology from bed to bench. 2018, 11(4): 284.

For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.

Live Biotherapeutics Drug Discovery

Online Inquiry

For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.

Contact us

Contact us

Copyright © 2022 Creative Biolabs. All Rights Reserved.

Inquiry Basket